Diagnose Early Revenue and Competitors
Estimated Revenue & Valuation
- Diagnose Early's estimated annual revenue is currently $7.1M per year.
- Diagnose Early's estimated revenue per employee is $155,000
Employee Data
- Diagnose Early has 46 Employees.
- Diagnose Early grew their employee count by 35% last year.
Diagnose Early's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Technology Officer | Reveal Email/Phone |
2 | Director IT & Security | CISO | Reveal Email/Phone |
3 | Director IT & Security | Reveal Email/Phone |
Diagnose Early Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Diagnose Early?
Founded by a Nobel Prize-winning team including Stanford M.D./Ph.D., Nobel Laureate, and a Harvard Business School/UW Madison Engineer. We are commercializing diagnostics for Cancer, Neurological, and Infectious Diseases, and are in clinical trials at Stanford University. The Diagnose Early team has patented a COVID-19 Acuity test titled D.E.C.A. that uses amino acid biomarkers found in breath to accurately and non-invasively predict the clinical course of each patient and therefore guide treatment.
keywords:N/AN/A
Total Funding
46
Number of Employees
$7.1M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.6M | 46 | 15% | N/A |
#2 | $3.5M | 46 | 24% | N/A |
#3 | $9.2M | 46 | 2% | N/A |
#4 | $9.9M | 46 | 0% | N/A |
#5 | $5.5M | 47 | 68% | N/A |
